Search PubMedSearch

Biomedical subjects

Rongrong Li

Publications and source records attributed to Rongrong Li.

2 recordsLinked to original sources

Natural variation in Miniature5 determines mitochondrial nad1 splicing and seed development in maize.

Seed size is a key determinant of cereal grain yield, but natural variations in defective-kernel genes have rarely been applied in maize breeding. Here, we report the positional cloning of maize Miniature5 (Mn5), which encodes a mitochondrial-targeted P-class pentatricopeptide repeat (PPR) protein. Further analysis shows that a missense mutation of Mn5, Mn5Val109, presents in maize populations and correlates with reduced seed size. The Mn5Val109 variant exhibits compromised function in the miniature5 (mn5-ref) mutant, failing to trans-splice mitochondrial nad1 intron1, drastically reducing the abundance and activity of respiratory complex I, accompanied by disorganized mitochondrial cristae. Mn5 directly binds to domain IV of the pre-nad1.1 transcript. Notably, this binding site is located downstream of the previously presumed 3'-terminus bound by MITOCHONDRIA STABILITY/PROCESSING PPR FACTOR1 (MSP1), thus redefining the 3'-end of the nad1.1 pre-RNA. Furthermore, Mn5 physically interacts with the maturases ZmnMAT1 and ZmnMAT3, as well as the PPR proteins PPR-SMR1 and SPR2, which are broadly involved in organellar group II intron splicing. Together, our results suggest that Mn5 recruits maturases and PPR proteins to form spliceosomal complexes responsible for the trans-splicing of nad1 intron1. Importantly, natural variations in Mn5 confer differences in seed size control, offering potential for breeding high-yield maize varieties.

Zea mays

NR2F6 regulates Temozolomide resistance in glioma via the E2F2-PARP1 pathway.

BACKGROUND: Glioma is the most common primary malignant brain tumor in adults. Temozolomide (TMZ) represents a standard-of-care chemotherapeutic agent in glioblastoma (GBM). However, the development of drug resistance constitutes a significant hurdle in the treatment of malignant glioma. Elucidating the mechanisms of temozolomide (TMZ) resistance in glioma is of critical clinical importance for improving patient prognosis and developing novel therapeutic strategies. METHODS: We obtained RNA sequencing (RNA-seq) data of 648 glioma samples from The Cancer Genome Atlas (TCGA) and 325 samples from the Chinese Glioma Genome Atlas (CGGA) as study cohorts. Additionally, we validated the expression characteristics of the NR2F6 gene in our in-house cohort of glioma patients. Furthermore, we investigated the potential mechanism of NR2F6 in TMZ resistance in glioma by constructing TMZ-resistant cell lines in vitro. Statistical analyses and graphical work were primarily performed using R language and GraphPad Prism software. RESULTS: We observed a significant upregulation of NR2F6 expression in high-grade gliomas, which is associated with an unfavorable prognosis in patients. Concurrently, our findings revealed a significant upregulation of NR2F6 in drug-resistant cells, which induced TMZ resistance in glioma cells via the E2F2-PARP1 axis. CONCLUSION: In brief, NR2F6, as a nuclear transcription factor, enhances the transcription of E2F2.The increased expression of E2F2 enhances PARP1 expression, which in turn facilitates TMZ-mediated DNA damage repair, thereby diminishing glioma sensitivity to TMZ.

Journal Article